Veraquel Technologies, spun out of Tufts University, is commercializing a platform technology for the synthesis and manufacturing of peptides, applicable from discovery to large-scale production. The company's patented technology has the potential to eliminate the need for labor-intensive column separations, altering the process of manufacturing scale-up and enabling the high-throughput parallel purification of peptides for library-based approaches to drug discovery.
